A pectin-like polysaccharide from Polygala tenuifolia inhibits pancreatic cancer cell growth in vitro and in vivo by inducing apoptosis and suppressing autophagy.
Animals
Apoptosis
/ drug effects
Autophagy
/ drug effects
Caspase 3
/ metabolism
Cell Line, Tumor
Cell Movement
/ drug effects
Cell Proliferation
/ drug effects
Humans
Immunohistochemistry
Mice, Inbred BALB C
Mice, Nude
Pancreatic Neoplasms
/ drug therapy
Pectins
/ pharmacology
Polygala
/ chemistry
Polysaccharides
/ isolation & purification
Xenograft Model Antitumor Assays
Apoptosis
Autophagy
Pancreatic cancer
Pectin
Polygala tenuifolia
Journal
International journal of biological macromolecules
ISSN: 1879-0003
Titre abrégé: Int J Biol Macromol
Pays: Netherlands
ID NLM: 7909578
Informations de publication
Date de publication:
01 Nov 2020
01 Nov 2020
Historique:
received:
21
02
2020
revised:
24
05
2020
accepted:
08
06
2020
pubmed:
13
6
2020
medline:
14
4
2021
entrez:
13
6
2020
Statut:
ppublish
Résumé
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignant carcinomas, which is characterized by apoptosis- and autophagy-dependent tumorigenic growth. Autophagy constitutes a stress adaptation that suppresses apoptosis. To explore new leading compound against PDAC, a pectin-like polysaccharide named RP02-1, was purified from roots of Polygala tenuifolia. Bioactivity test showed that RP02-1 might inhibit pancreatic cancer cells growth in vitro and in vivo. RP02-1 could inhibit pancreatic cancer cell (AsPC-1 and BxPC-3) proliferation, migration and colony formation. Mechanism study suggested that RP02-1 induced pancreatic cancer cells apoptosis, which was detected by Bcl-2 down-regulation, Bax up-regulation and conversion from Caspase 3 to Cleaved Caspase 3. Interestingly, autophagy was suppressed by RP02-1 treatment concentration-dependently through affenuatingBeclin-1, ATG5 and LC3B expression in BxPC-3 cells. In addition, RP02-1 could inhibit autophagy induced by Pennogenin 3-O-beta-chacotrioside. However, RP02-1 had almost no toxicity both in vitro and in vivo. The above results suggested that RP02-1 might be a potential leading compound for new drug candidate development for human PDAC treatment via inducing apoptosis and against autophagy.
Identifiants
pubmed: 32531363
pii: S0141-8130(20)33495-4
doi: 10.1016/j.ijbiomac.2020.06.054
pii:
doi:
Substances chimiques
Polysaccharides
0
Pectins
89NA02M4RX
CASP3 protein, human
EC 3.4.22.-
Caspase 3
EC 3.4.22.-
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
107-115Informations de copyright
Copyright © 2020 Elsevier B.V. All rights reserved.